Roche pays $250 million to acquire Good Therapeutics and its preclinical cancer therapy

Good Therapeutics, a private company that raised just $30 million in venture financing since its 2016 foundation, said Wednesday it had signed a deal to sell itself to Roche for $250 million without ever running a clinical trial.